Inositol phospholipid-specific phospholipases C (PLCs) catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdInsP 2 ) to produce inositol 1,4,5-trisphosphate (InsP 3 ) and diacylglycerol (DAG). The enzymes thus produce three immediate intracellular messages: increased InsP 3 (and, consequently, a rise in intracellular Ca 2+ ), increased DAG (causing enhanced activity of protein kinases C), and decreased PtdInsP 2 . The local concentration of the latter in the plasma membrane and, possibly, in other cellular membranes regulates the activities and/or subcellular distribution of many regulatory or structural proteins, including enzymes, ion channels and transporters, transcription factors, scaffolding proteins, and cytoskeletal proteins. The thirteen mammalian PLC isozymes are divided into six subfamilies, designated b, g, d, ε, z, and h (Kadamur and Ross, 2012) . The four members of the PLCb subfamily are activated by heterotrimeric G protein Ga q and Gbg subunits as well as, in the case of PLCb 2 , by the Rho GTPases Rac and Cdc42. The two members of the PLCg family, g 1 and g 2 , are activated by receptor and nonreceptor protein-tyrosine kinases. PLCg 2 , but not PLCg 1 , is also activated by Rac. In addition, alternative mechanisms exist to regulate the activity of the two PLCg isoforms. The regulation of the other PLC isoforms (d-h) is less clear, although they too may be activated by increased intracellular Ca 2+ (d-h), heterotrimeric G protein subunits (ε, h), and small GTP-binding proteins (d, ε) . Intriguingly, some of the cellular functions of PLCg isozymes appear to be independent of their catalytic activity (e.g., Swiercz et al., 2009) .
The molecular mechanisms of activation of the PLC isozymes in intact cells, in particular by regulatory proteins and by tyrosine phosphorylation, have long been obscure and have only recently been elucidated by structural studies. Thus, analysis of the three-dimensional structure of a truncated form of PLCb 2 revealed that the active site of the enzyme is occluded by a small segment of the region separating the two halves (X and Y) of the catalytic triose phosphate isomerase barrel (Hicks et al., 2008) . Deletion of this segment constitutively activates PLCb 2 without ablating its capacity to be further stimulated by Ga q , Gbg, or Rac. Similar regulation occurs in other PLC members (d, ε) . This has led to the proposal of a general mechanism of interfacial PLC isozyme activation. According to this model, the various protein activators would anchor and orient the PLCs at substrate membranes to release autoinhibition by the XY linker and to promote access of PtdInsP 2 to the lipase active site. However, several lines of evidence suggest that other mechanisms of PLC autoinhibition and activation exist, even for PLCb (Lyon et al., 2011) , but also for PLCz (Nomikos et al., 2012 ) and the PLCg isozymes, which do not contain negative charges in their XY linkers at the high density critical in other PLCs for interfacial activation and are not activated by deletion of a segment corresponding to the autoinhibitory XY linker segment of PLCb 2 (unpublished data).
The sequence linking X and Y in PLCg isozymes is unique and encodes a modular tandem comprising, in this order, the N-terminal half of a split PH domain (nsPH), an N-terminal SH2 domain (nSH2), a C-terminal SH2 domain (cSH2), an SH3 domain, and the C-terminal half of the spPH domain (csPH). The whole tandem is also referred to as specific array (SA). Previous results on the activation of PLCg 1 by tyrosine phosphorylation have shown that nSH2 is important for recognition of phosphorylated tyrosine residues on activated cell surface tyrosine kinase receptors, whereas cSH2 interacts, in an intramolecular fashion, with the major phosphorylated tyrosine of PLCg 1 , Y783, located immediately downstream of cSH2 (Poulin et al., 2005; Gresset et al., 2010) .
The work by Bunney et al. (2012) N-labeled nSH2, cSH2, and spPH with the PLCg 1 core lacking SA was examined by NMR titration. Most intriguingly, only cSH2 showed changes in its NMR spectrum, and these changes were completely reversed in the presence of the phosphorylated cSH2-SH3 linker peptide containing pY783. These findings and other evidence imply that cSH2 is, in fact, the only SA constituent that interacts with the PLCg 1 core containing its catalytic domain and that this interaction can be released following Y783 phosphorylation and intramolecular association with the cSH2 domain. Finally, the authors used biochemical experiments to demonstrate that the association of wild-type, full-length PLCg 1 with activated FGFR-1 is greatly decreased following PLCg 1 phosphorylation and that phosphorylated, isolated PLCg 1 retains high activity without the requirement of sustained binding to activated FGFR-1.
The findings reported in this work have several important implications. First, they strongly suggest a model of PLCg 1 activation by tyrosine kinase growth factor receptors, consisting of an initial and transient strong interaction between the receptor and PLCg 1 , mediated by nSH2, followed by phosphorylation of PLCg 1 cSH2-mediated release of catalytically active PLCg 1 from the receptor, and, possibly, processive phosphorylation of many PLCg 1 molecules by a single activated receptor. Depending on the relative lifetimes of the activated states of the individual proteins, this could lead to signal amplification at a very early step of signal transduction, similar to that observed, in many cases, for the activation of heterotrimeric G proteins by their receptors (e.g., Arshavsky et al., 2002) . Second, the structural alterations observed in the PLCg 1 SA during receptormediated activation may help to understand the molecular mechanisms involved in activation of PLCg 2 by chemically induced or spontaneously occurring mutations in the mouse Plcg2 and the human PLCG2 genes, respectively, and giving rise to specific autoimmune diseases in mice and humans, such as cold-induced urticaria and immune dysregulation (see Zhou et al., 2012 for references). Intriguingly, several of these mutations map to cSH2 or the interface between csPH and cSH2, as determined in the study reported in this issue.
It seems clear that this work leaves certain aspects open and raises new questions. For example, it is unclear to what extent the findings reported here for PLCg 1 can be extrapolated to PLCg 2 , which plays important, specific roles in, e.g., B cells, monocytes/macrophages, mast cells, and platelets. Analysis in intact B cells suggests that phosphorylation of more than one site may be required for full enzyme activation (e.g., Watanabe et al., 2001) . Second, the functional roles of the other PLCg 1 SA constituents, such as sPH and SH3, and phosphorylation(s) of PLCg 1 at sites potentially functionally relevant in other cellular contexts and for other types of stimuli, such as Y775 and Y1253, remain to be integrated into the model suggested here. Finally, many of the results presented in this paper were (and had to be) done in transfected cells or cell-free preparations. It is clear that experiments in native cells will be required to determine the validity of the concepts derived in this very elegant study for the behavior of PLCg 1 in natural plasma membranes and more complex cellular environments.
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